These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11249722)

  • 1. Fampridine Acorda Therapeutics.
    Darlington C
    Curr Opin Investig Drugs; 2000 Nov; 1(3):375-9. PubMed ID: 11249722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fampridine-SR for multiple sclerosis and spinal cord injury.
    Hayes KC
    Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
    Korenke AR; Rivey MP; Allington DR
    Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained release oral fampridine in the treatment of multiple sclerosis.
    Kachuck NJ
    Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury.
    Cardenas DD; Ditunno JF; Graziani V; McLain AB; Lammertse DP; Potter PJ; Alexander MS; Cohen R; Blight AR
    Spinal Cord; 2014 Jan; 52(1):70-6. PubMed ID: 24216616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained-release fampridine for multiple sclerosis.
    Bever CT; Judge SI
    Expert Opin Investig Drugs; 2009 Jul; 18(7):1013-24. PubMed ID: 19548855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiazofurine ICN Pharmaceuticals.
    Grifantini M
    Curr Opin Investig Drugs; 2000 Oct; 1(2):257-62. PubMed ID: 11249583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Cardenas DD; Ditunno J; Graziani V; Jackson AB; Lammertse D; Potter P; Sipski M; Cohen R; Blight AR
    Spinal Cord; 2007 Feb; 45(2):158-68. PubMed ID: 16773037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
    Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR
    Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
    Potter PJ; Hayes KC; Segal JL; Hsieh JT; Brunnemann SR; Delaney GA; Tierney DS; Mason D
    J Neurotrauma; 1998 Oct; 15(10):837-49. PubMed ID: 9814639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brasofensine NeuroSearch.
    Yu P
    Curr Opin Investig Drugs; 2000 Dec; 1(4):504-7. PubMed ID: 11249705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Citicoline. Ferrer Internacional.
    Alexandrov AV
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1757-62. PubMed ID: 11892942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
    Fernandez O; Berger T; Hartung HP; Putzki N
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):649-65. PubMed ID: 23146002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exisulind Cell Pathways.
    Griffiths GJ
    Curr Opin Investig Drugs; 2000 Nov; 1(3):386-91. PubMed ID: 11249724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term 4-aminopyridine therapy on glucose tolerance and glucokinetics in patients with spinal cord injury.
    Segal JL; Thompson JF; Tayek JA
    Pharmacotherapy; 2007 Jun; 27(6):789-92. PubMed ID: 17542761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZD-0473 AstraZeneca.
    Hay MP
    Curr Opin Investig Drugs; 2000 Oct; 1(2):263-6. PubMed ID: 11249584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
    Cornblath DR; Bienen EJ; Blight AR
    Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymitaq (Zarix).
    Niculescu-Duvaz I
    Curr Opin Investig Drugs; 2001 May; 2(5):693-705. PubMed ID: 11569949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.